Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenbaum, C. J.
Right arrow Articles by Palmer, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenbaum, C. J.
Right arrow Articles by Palmer, J. P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 48, Issue 1 170-175, Copyright © 1999 by American Diabetes Association

ARTICLES

Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study

CJ Greenbaum, KL Sears, SE Kahn and JP Palmer
Department of Medicine, University of Washington, Seattle, USA. carlag@u.washington.edu

A total of 85 islet cell antibody (ICA)+ or insulin autoantibody (IAA)+ relatives of patients with type 1 diabetes have been followed as part of the Seattle Family Study for a mean of 2.8 years. Of the subjects followed, 10 developed diabetes during this time period. The presence of GAD antibodies was strongly associated with the development of diabetes. In contrast, the presence of IAAs did not influence the risk of diabetes among ICA+ GAD+ subjects. When either the initial absolute acute insulin response to glucose (AIRg) or the AIR percentile, which accounts for the individual's insulin sensitivity, was below the 10th percentile of normal subjects, the risk of diabetes approached 50% at 5 years. However, impaired beta-cell function did not influence the risk of diabetes among those who were GAD+. There were 13 subjects with low AIRg and 13 subjects with two or more antibodies who had not progressed to diabetes during the course of the study. Other measurements of beta-cell function or demographic characteristics were not different in this group of nonprogressors compared with those with low AIRg who did not progress to diabetes. We conclude that ICA+ relatives with GAD antibodies or low AIRg have a high risk for development of diabetes, but among ICA+ GAD+ relatives, the addition of IAA or a single determination of AIRg does not enhance the prediction of diabetes. We suggest that prediction of diabetes risk depends on both the type and the number of antibodies present. In addition, there are a group of ICA+ relatives with low AIRg and/or multiple antibodies who have not progressed to diabetes over the course of the study.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
P. Xu, D. Cuthbertson, C. Greenbaum, J. P. Palmer, J. P. Krischer, and for the Diabetes Prevention Trial Type 1 Study Gro
Role of Insulin Resistance in Predicting Progression to Type 1 Diabetes
Diabetes Care, September 1, 2007; 30(9): 2314 - 2320.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. M. Sosenko, J. P. Palmer, C. J. Greenbaum, J. Mahon, C. Cowie, J. P. Krischer, H. P. Chase, N. H. White, B. Buckingham, K. C. Herold, et al.
Increasing the Accuracy of Oral Glucose Tolerance Testing and Extending Its Application to Individuals With Normal Glucose Tolerance for the Prediction of Type 1 Diabetes: The Diabetes Prevention Trial-Type 1
Diabetes Care, January 1, 2007; 30(1): 38 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
The STOPP-T2D Prevention Study Group
Presence of Diabetes Risk Factors in a Large U.S. Eighth-Grade Cohort
Diabetes Care, February 1, 2006; 29(2): 212 - 217.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. Pihoker, L. K. Gilliam, C. S. Hampe, and A. Lernmark
Autoantibodies in Diabetes
Diabetes, December 1, 2005; 54(suppl_2): S52 - S61.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. A. Atkinson
Thirty Years of Investigating the Autoimmune Basis for Type 1 Diabetes: Why Can't We Prevent or Reverse This Disease?
Diabetes, May 1, 2005; 54(5): 1253 - 1263.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. T. Robles, G. S. Eisenbarth, N. J.M. Dailey, L. B. Peterson, and L. S. Wicker
Insulin Autoantibodies Are Associated With Islet Inflammation But Not Always Related to Diabetes Progression in NOD Congenic Mice
Diabetes, March 1, 2003; 52(3): 882 - 886.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. P. Krischer, D. D. Cuthbertson, L. Yu, T. Orban, N. Maclaren, R. Jackson, W. E. Winter, D. A. Schatz, J. P. Palmer, and G. S. Eisenbarth
Screening Strategies for the Identification of Multiple Antibody-Positive Relatives of Individuals with Type 1 Diabetes
J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 103 - 108.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
W. E. Winter, N. Harris, and D. Schatz
Immunological Markers in the Diagnosis and Prediction of Autoimmune Type 1a Diabetes
Clin. Diabetes, October 1, 2002; 20(4): 183 - 191.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. J. Greenbaum, R. L. Prigeon, and D. A. D'Alessio
Impaired {beta}-Cell Function, Incretin Effect, and Glucagon Suppression in Patients With Type 1 Diabetes Who Have Normal Fasting Glucose
Diabetes, April 1, 2002; 51(4): 951 - 957.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
L. Yu, D. D. Cuthbertson, N. Maclaren, R. Jackson, J. P. Palmer, T. Orban, G. S. Eisenbarth, and J. P. Krischer
Expression of GAD65 and Islet Cell Antibody (ICA512) Autoantibodies Among Cytoplasmic ICA+ Relatives Is Associated With Eligibility for the Diabetes Prevention Trial-Type 1
Diabetes, August 1, 2001; 50(8): 1735 - 1740.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Rickert, J. Seissler, W. Dangel, H. Lorenz, and W. Richter
Fusion Proteins for Combined Analysis of Autoantibodies to the 65-kDa Isoform of Glutamic Acid Decarboxylase and Islet Antigen-2 in Insulin-dependent Diabetes Mellitus
Clin. Chem., May 1, 2001; 47(5): 926 - 934.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. S. Hampe, L. P. Hammerle, L. Bekris, E. Örtqvist, I. Kockum, O. Rolandsson, M. Landin-Olsson, C. Törn, B. Persson, and A. Lernmark
Recognition of Glutamic Acid Decarboxylase (GAD) by Autoantibodies from Different GAD Antibody-Positive Phenotypes
J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4671 - 4679.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Yu, L. Yu, T. L. Bugawan, H. A. Erlich, K. Barriga, M. Hoffman, M. Rewers, and G. S. Eisenbarth
Transient Antiislet Autoantibodies: Infrequent Occurrence and Lack of Association with "Genetic" Risk Factors
J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2421 - 2428.
[Abstract] [Full Text]

Home page
 NEJMHome page
A. Lernmark
Rapid-Onset Type 1 Diabetes with Pancreatic Exocrine Dysfunction
N. Engl. J. Med., February 3, 2000; 342(5): 344 - 345.
[Full Text]

Home page
 Clin. Chem.Home page
A. Lernmark
Type 1 Diabetes
Clin. Chem., August 1, 1999; 45(8): 1331 - 1338.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1999 by the American Diabetes Association.